新型抗糖尿病药物FFA1受体激动剂的研究进展  

Recent Developments of FFA1 Receptor Agonists as Novel Anti-diabetic Drugs

作　　者：陆琰[1] 周金培[1] 

机构地区：[1]中国药科大学,南京210009

出　　处：《海峡药学》2016年第4期4-8,共5页Strait Pharmaceutical Journal

摘　　要：尽管目前建立的治疗Ⅱ型糖尿病的治疗方案取得了一定成效,但是仍然没有满足人类对新型的更加安全有效的抗糖尿病药物的需求。在这个领域FFA1受体已成为近年来一个很有吸引力的靶标。FFA1受体不仅通过刺激胰岛β细胞促使胰岛素分泌,同时能作用于场内分泌细胞促使肠促胰岛素分泌。最新的研究进展和临床数据表明,FFA1受体激动剂是治疗Ⅱ型糖尿病的潜力药物。Despite the availability of established medication for treatment of type 2 diabetes mellitus（ T2DM）there still remains a significant unmet need for new effective,oral antidiabetic agents that improve glycemic control while maintaining an excellent safety profile. In this regard the FFA1 receptor has emerged as an attractive target in recent years. Activation of the FFA1 receptor has been shown to not only amplify glucose induced insulin secretion from pancreatic beta cells but also to stimulate incretin secretion from intestinal endocrine cells. The current review highlights on the latest developments and clinical data from evolving research on the potential of FFA1 agonists as effective treatment for T2 DM.

关 键 词：Ⅱ型糖尿病 FFA1受体 胰岛素 GPR40 激动剂 

分 类 号：R965[医药卫生—药理学]